rs367543005 — ASL p.Gln354Ter (Q354X)

ASL Q354X — A Founder Allele That Silences the Urea Cycle's Fourth Step

Every amino acid your body breaks down for energy releases nitrogen in the form of ammonia — a molecule that is toxic to the brain even at low concentrations. The urea cycle¹¹ urea cycle
A five-enzyme sequence in liver cells that converts ammonia to urea, which is then excreted in urine; collectively handles ~90% of the body's waste nitrogen exists to neutralize this steady stream of ammonia before it reaches the bloodstream. Argininosuccinate lyase (ASL) performs the fourth step: cleaving argininosuccinate into arginine and fumarate. When this step fails, argininosuccinate accumulates in blood and urine, the cycle backs up, and ammonia rises. ASL deficiency (argininosuccinic aciduria, or ASA) is the second most common urea cycle disorder, estimated at ~1 in 70,000 live births globally²² second most common urea cycle disorder, estimated at ~1 in 70,000 live births globally.

The Q354X variant (c.1060C>T in the canonical transcript; classified as a stop-gained variant at GRCh38 chr7:66089693³³ stop-gained variant at GRCh38 chr7:66089693) introduces a premature stop codon at position 354 of the 464-amino-acid ASL protein. The truncated protein is non-functional: the C-terminal region it loses contains critical residues for the enzyme's tetrameric assembly and catalytic activity. Q354X is listed as Pathogenic in ClinVar (VCV000021253)⁴⁴ Pathogenic in ClinVar (VCV000021253) with multiple submitters and no conflicts.

The Mechanism

ASL catalyzes the reversible elimination of fumarate from argininosuccinate, yielding arginine. In its normal form, the enzyme assembles as a homotetramer, and the active sites sit at subunit interfaces — a structural arrangement that makes even partial loss of functional subunits disproportionately disruptive. The Q354X truncation eliminates the C-terminal segment entirely, preventing correct folding and tetramer formation. The result is a complete loss of enzymatic activity from the Q354X allele.

Beyond the urea cycle bottleneck, ASL has a second metabolic role that explains some of its most distinctive clinical features. Nagamani et al. 2012 (AJHG)⁵⁵ Nagamani et al. 2012 (AJHG)
Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. Am J Hum Genet 2012;90:836-46 demonstrated that ASL is required not just for urea synthesis but for channeling arginine to nitric oxide synthase (NOS) for nitric oxide production. Without functional ASL, nitric oxide (NO)⁶⁶ nitric oxide (NO)
The endothelial signaling molecule essential for blood vessel relaxation and blood pressure regulation; produced when NOS converts arginine to citrulline synthesis is impaired even when plasma arginine levels appear adequate. This NO deficiency causes systemic hypertension that can be refractory to conventional antihypertensives — a complication specific to ASL deficiency and largely absent in other urea cycle disorders where ASL is intact.

The Evidence

Q354X was characterized as a Saudi founder mutation by Al-Sayed et al. 2005⁷⁷ Al-Sayed et al. 2005
Identification of a common novel mutation in Saudi patients with argininosuccinic aciduria. J Inherit Metab Dis 2005, who found the allele in 14 of 28 Saudi ASA patients — representing approximately 50% of abnormal ASL alleles in their cohort. The authors recommended routine testing for Q354X and Q116X in all ASA patients of Arab origin. This high allele frequency in Saudi patients, combined with near-absence in non-Arab populations (no observed instances in large European, East Asian, or African cohorts in gnomAD), confirms its founder mutation status.

The largest Saudi clinical series, AlTassan et al. 2018⁸⁸ AlTassan et al. 2018
European Journal of Medical Genetics, n=54 patients, confirmed Q354X as the dominant variant. Q354X homozygotes had a higher frequency of hyperammonemia episodes than patients with other mutations. Despite 92% receiving early diagnosis (before 28 days through newborn screening), 90.7% developed developmental delay and 62.9% had seizure disorders by the time of review (mean age 10 years), illustrating that ammonia control during neonatal crises is necessary but not sufficient to prevent long-term neurocognitive damage. Thrombocytosis was unexpectedly prevalent (96%), a finding without clear mechanistic explanation.

A long-term Austrian cohort study (n=17, median age 13 years) Mercimek-Mahmutoglu et al. 2010⁹⁹ Mercimek-Mahmutoglu et al. 2010
Mol Genet Metab 2010 documented more favorable outcomes in newborn-screened patients, with 65% achieving average or above-average IQ — an important benchmark for what aggressive early management can achieve. However, three patients still developed hepatic steatosis, underscoring that liver complications emerge independent of ammonia control.

A key finding across studies: there is no correlation between genotype, enzyme activity, and clinical outcome¹⁰¹⁰ no correlation between genotype, enzyme activity, and clinical outcome in ASL deficiency. Q354X homozygosity cannot predict clinical severity in an individual, which is why ongoing monitoring rather than genotype-alone decision-making guides management.

Practical Actions

ASL deficiency is diagnosed in the neonatal period through newborn screening via elevated citrulline and argininosuccinic acid on tandem mass spectrometry. Affected individuals presenting for the first time through a genome report are almost certainly already under specialist metabolic care. The management summary below reflects established clinical practice:

Unlike most other urea cycle disorders, ASL deficiency requires arginine supplementation rather than restriction — because the urea cycle stalls before arginine is produced, affected individuals cannot synthesize adequate arginine endogenously and must receive exogenous free-base arginine to meet cellular needs while simultaneously providing a substrate cycle that allows some residual nitrogen clearance.

Long-term complications extend beyond ammonia: hepatic fibrosis, steatosis, and systemic hypertension all occur at higher rates than in the general population and require dedicated monitoring independent of plasma ammonia levels.

Interactions

Within the ASL gene, compound heterozygosity — carrying Q354X on one chromosome and a different pathogenic ASL allele on the other — produces clinical ASL deficiency identical to Q354X homozygosity. The Al-Sayed 2005 study documented compound Q354X/Q116X cases in Saudi patients. All compound heterozygous combinations of two null alleles carry the same management requirements.

The Q354X lesion sits at the fourth step of the urea cycle, which depends on substrate delivery from the three preceding steps (CPS1, OTC, ASS1). Variants in those upstream enzymes do not compound the severity of Q354X deficiency — the Q354X block is itself complete and rate-limiting. Downstream, the loss of arginine production impairs the nitric oxide synthase pathway (eNOS, nNOS), producing secondary NO deficiency-mediated cardiovascular and neurological effects that are specific to ASL among urea cycle disorders.